{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:50:04Z","timestamp":1770969004496,"version":"3.50.1"},"reference-count":93,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: There is currently no clear evidence of the effectiveness of antibiotic therapy in acute ocular toxoplasmosis (OT), but its effect as a secondary prophylaxis is undisputed. The majority of uveitis specialists advocate treatment. This meta-analytic review aims to critically analyze determinants of treatment success and to update current treatment strategies for OT in order to explain this discrepancy. Methods: A systematic literature search was performed in NCBI\/PubMed, Clinical Trials, Google Scholar and ScienceDirect to retrieve pro- and retrospective studies using the key terms \u201cocular toxoplasmosis\u201d or \u201cretinochoroiditis\u201d and \u201cimmunocompetent\u201d and \u201ctreatment\u201d or \u201ctherapy\u201d and \u201chuman.\u201d Of these, larger case series and prospective clinical studies and cross references identified from meta-analyses were selected by a manual search, and primary and secondary outcome parameters were extracted. Results: Ten case series and clinical trials reported success parameters for treatment outcomes, and four additional for recurrence prophylaxis. Five treatment studies were randomized clinical trials, three comparative and two noncomparative case series. Though several outcome parameters were reported, five of them defined time to healing, four visual gain and one lesion size as primary and secondary outcome parameters, recurrence rate as a secondary outcome parameter was reported once. No conclusive evidence was found for an antibiotic treatment effect. Four prophylaxis studies addressed the prevention of recurrences after treatment. The primary outcome in all studies was the effect of treatment and prophylaxis on recurrences, and all four found a significant effect on the risk of and time to recurrences. Conclusions: Antibiotic treatment of OT aims at controlling parasite proliferation. The absence of an effect on visual acuity and time to healing is thus not surprising. The fact that time to and number of recurrences respond to recurrence of prophylaxis proves the antibiotic effect on parasite activity.<\/jats:p>","DOI":"10.3390\/jcm10051090","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T11:46:09Z","timestamp":1614944769000},"page":"1090","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment Strategy in Human Ocular Toxoplasmosis: Why Antibiotics Have Failed"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"first","affiliation":[{"name":"Swiss Eye Institute, Rotkreuz, and Uveitis Clinic, Berner Augenklinik am Lindenhofspital, 3012 Bern, Switzerland"},{"name":"Department of Ophthalmology, Inselspital, University of Bern, 3012 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Campus Virchow, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin and Berlin Institute of Health, Charit\u00e9, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1442-9071.2012.02821.x","article-title":"Ocular toxoplasmosis I: Parasitology, epidemiology and public health","volume":"41","author":"Furtado","year":"2013","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/09273948.2012.661115","article-title":"Epidemiology of Ocular Toxoplasmosis","volume":"20","author":"Petersen","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.preteyeres.2013.12.005","article-title":"Ocular toxoplasmosis past, present and new aspects of an old disease","volume":"39","author":"Maenz","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2011.331","article-title":"Toxoplasmosis: New challenges for an old disease","volume":"26","author":"Bodaghi","year":"2012","journal-title":"Eye"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ajo.2008.06.027","article-title":"Respective Roles of Acquired and Congenital Infections in Presumed Ocular Toxoplasmosis","volume":"146","author":"Delair","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/cid\/ciu793","article-title":"Ocular Toxoplasmosis in the United States: Recent and Remote Infections","volume":"60","author":"Jones","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/ICU.0b013e328358bae5","article-title":"Ocular manifestations of systemic disease: Toxoplasmosis","volume":"23","year":"2012","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ajo.2003.09.040","article-title":"Ocular toxoplasmosis: A global reassessment. Part I. Epidemiology and course of disease","volume":"136","author":"Holland","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fcimb.2019.00413","article-title":"Influence of Two Major Toxoplasma Gondii Virulence Factors (ROP16 and ROP18) on the Immune Response of Peripheral Blood Mononuclear Cells to Human Toxoplasmosis Infection","volume":"9","author":"Arenas","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rochet, E., Argy, N., Greigert, V., Brunet, J., Sabou, M., Marcellin, L., De-La-Torre, A., Sauer, A., Candolfi, E., and Pfaff, A.W. (2019). Type I ROP16 regulates retinal inflammatory responses during ocular toxoplasmosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214310"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.imlet.2011.04.007","article-title":"Humoral responses and immune protection in mice immunized with irradiated T. gondii tachyzoites and challenged with three genetically distinct strains of T. gondii","volume":"138","author":"Zorgi","year":"2011","journal-title":"Immunol Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.meegid.2016.06.053","article-title":"Host and Toxoplasma gondii genetic and non-genetic factors influencing the development of ocular toxoplasmosis: A systematic review","volume":"44","author":"Jaimes","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/INF.0000000000001978","article-title":"Decline of Seroprevalence and Incidence of Congenital Toxoplasmosis Despite Changing Prevention Policy\u2014Three Decades of Cord-blood Screening in North-western Switzerland","volume":"37","author":"Rudin","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1017\/S0950268813002756","article-title":"Incidence and prevalence of Toxoplasma gondii infection in women in France, 1980\u20132020: Model-based estimation","volume":"142","author":"Nogareda","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1017\/S0950268810001044","article-title":"Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in The Netherlands between 1995\/1996 and 2006\/2007","volume":"139","author":"Hofhuis","year":"2010","journal-title":"Epidemiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2007.77.405","article-title":"Toxoplasma gondii Infection in the United States, 1999\u20132004, Decline from the Prior Decade","volume":"77","author":"Jones","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4269\/ajtmh.14-0013","article-title":"Toxoplasma gondii Seroprevalence in the United States 2009\u20132010 and Comparison with the Past Two Decades","volume":"90","author":"Jones","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4269\/ajtmh.17-0677","article-title":"Toxoplasma gondii Infection in the United States, 2011\u20132014","volume":"98","author":"Jones","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22551","DOI":"10.1038\/srep22551","article-title":"Prevalence, incidence estimations and risk factors of Toxoplasma gondii infection in Germany: A representative, cross-sectional, serological study","volume":"6","author":"Wilking","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ajo.2015.04.005","article-title":"Ocular Toxoplasmosis: Lessons from Brazil","volume":"159","author":"Grigg","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4269\/ajtmh.2010.09-0664","article-title":"Annual burden of ocular toxoplasmosis in the US","volume":"82","author":"Jones","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/20477724.2018.1552644","article-title":"Patient and treatment pathways for toxoplasmosis in the United States: Data analysis of the Vizient Health Systems Data from 2011 to 2017","volume":"112","author":"Belk","year":"2018","journal-title":"Pathog. Glob. Heal."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00417-019-04416-w","article-title":"Posterior segment eye lesions: Prevalence and associations with ocular and systemic parameters: Results from the Gutenberg Health Study","volume":"257","author":"Elbaz","year":"2019","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.12659\/MSM.910749","article-title":"A Retrospective Observational Study of Uveitis in a Single Center in Poland with a Review of Findings in Europe","volume":"24","author":"Moskal","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-69078-9","article-title":"Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: A systematic review, modelling and meta-analysis","volume":"10","author":"Bigna","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/eye.2008.219","article-title":"Incidence and clinical characteristics in a Colombian cohort of ocular toxoplasmosis","volume":"23","year":"2009","journal-title":"Eye"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0002-9394(14)73976-5","article-title":"An Unusually High Prevalence of Ocular Toxoplasmosis in Southern Brazil","volume":"114","author":"Glasner","year":"1992","journal-title":"Am. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0002-9394(00)00830-8","article-title":"A follow-up study of Toxoplasma gondii infection in southern Brazil","volume":"131","author":"Silveira","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1442-9071.2009.02082.x","article-title":"Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia","volume":"37","author":"Rueda","year":"2009","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_30","first-page":"1","article-title":"Clinical, Socio-economic and Environmental Factors Related with Recurrences in Ocular Toxoplasmosis in Quind\u00edo, Colombia","volume":"2020","author":"Erira","year":"2020","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jfo.2013.11.007","article-title":"Int\u00e9r\u00eat du d\u00e9pistage ophtalmologique syst\u00e9matique de la toxoplasmose cong\u00e9nitale: \u00c9tude d\u2019une cohorte alsacienne entre 1990 et 2011","volume":"37","author":"Villard","year":"2014","journal-title":"J. Fran\u00e7ais d\u2019Ophtalmologie"},{"key":"ref_32","first-page":"435","article-title":"Toxoplasmosis in Germany: Epidemiology, Diagnosis, Risk Factors, and Treatment","volume":"116","author":"Pleyer","year":"2019","journal-title":"Dtsch. Aerzteblatt Online"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sagel, U., Kr\u00e4mer, A., and Mikolajczyk, R.T. (2011). Incidence of maternal Toxoplasma infections in pregnancy in Upper Austria, 2000\u20132007. BMC Infect. Dis., 11.","DOI":"10.1186\/1471-2334-11-348"},{"key":"ref_34","first-page":"CD002218","article-title":"Antibiotics versus no treatment for toxoplasma retinochoroiditis","volume":"2016","author":"Pradhan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","first-page":"CD007417","article-title":"Corticosteroids as adjuvant therapy for ocular toxoplasmosis","volume":"1","author":"Jasper","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ophtha.2012.07.061","article-title":"Interventions for toxoplasma retinochoroiditis: A report by the American Academy of Ophthalmology","volume":"120","author":"Kim","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-3024.2005.00747.x","article-title":"Determinants of immunodiagnostic success in human ocular toxoplasmosis","volume":"27","author":"Garweg","year":"2005","journal-title":"Parasite Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijpara.2013.04.004","article-title":"The local immune response to intraocular Toxoplasma re-challenge: Less pathology and better parasite control through Treg\/Th1\/Th2 induction","volume":"43","author":"Sauer","year":"2013","journal-title":"Int. J. Parasitol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9356728","DOI":"10.1155\/2019\/9356728","article-title":"Immune Mediator Profile in Aqueous Humor Differs in Patients with Primary Acquired Ocular Toxoplasmosis and Recurrent Acute Ocular Toxoplasmosis","volume":"2019","author":"Thieme","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/09273948.2013.779724","article-title":"Therapy for ocular toxoplasmosis-the future","volume":"21","author":"Garweg","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9394(02)01527-1","article-title":"The effect of long-term intermittent trimethoprim\/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis","volume":"134","author":"Silveira","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/09273948.2014.964422","article-title":"The Effect of Long-term Intermittent Trimethoprim\/Sulfamethoxazole Treatment on Recurrences of Toxoplasmic Retinochoroiditis: 10 Years of Follow-up","volume":"23","author":"Silveira","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ajo.2016.08.003","article-title":"Trimethoprim-Sulfamethoxazole versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up","volume":"170","author":"Felix","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ajo.2019.12.025","article-title":"Long-term Results of Trimethoprim-Sulfamethoxazole versus Placebo to Reduce the Risk of Recurrent Toxoplasma gondii Retinochoroiditis","volume":"213","author":"Felix","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bjo.40.10.577","article-title":"Treatment of Uveitis with Pyrimethamine (Daraprim)","volume":"40","author":"Perkins","year":"1956","journal-title":"Br. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archopht.1964.00970010074010","article-title":"Toxoplasmic Retinochoroiditis: A Double Blind Therapeutic Study","volume":"71","author":"Acers","year":"1964","journal-title":"Arch. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0002-9394(65)95020-8","article-title":"Therapy of Toxoplasmosis Uveitis","volume":"59","author":"Ghosh","year":"1965","journal-title":"Am. J. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/bjo.52.5.396","article-title":"Treatment of active toxoplasmic retino-choroiditis","volume":"52","author":"Nolan","year":"1968","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","first-page":"161","article-title":"Chorior\u00e9tinites pr\u00e9sum\u00e9es toxoplasmiques: Etude comparative des traitements par pyrim\u00e9thamine et sul-fadiazine ou clindamycine","volume":"12","author":"Colin","year":"1989","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ophtha.2005.05.025","article-title":"Prospective Randomized Trial of Trimethoprim\/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the Treatment of Ocular Toxoplasmosis","volume":"112","author":"Soheilian","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5935\/0004-2749.20150056","article-title":"Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone","volume":"78","author":"Zamora","year":"2015","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.joco.2016.10.002","article-title":"A prospective randomized trial of azithromycin versus trimethoprim\/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis","volume":"29","author":"Lashay","year":"2017","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/APO.0000000000000244","article-title":"Ocular Toxoplasmosis in a Tertiary Referral Center in Sydney Australia\u2014Clinical Features, Treatment, and Prognosis","volume":"8","author":"Yates","year":"2019","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/09273948.2019.1569242","article-title":"Effectiveness of Treatments for Ocular Toxoplasmosis","volume":"28","author":"Casoy","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bjophthalmol-2015-306650","article-title":"Influence of drug therapy on the risk of recurrence of ocular toxoplasmosis","volume":"100","author":"Reich","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Borkowski, P.K., Brydak-Godowska, J., Basiak, W., \u015awitaj, K., \u017barnowska-Prymek, H., Olszy\u0144ska-Krowicka, M., Kajfasz, P., and Rabczenko, D. (2016). The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004892"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Arantes, T.E., Silveira, C., Holland, G.N., Muccioli, C., Yu, F., Jones, J.L., Goldhardt, R., Lewis, K.G., and Belfort, R. (2015). Ocular Involvement Following Postnatally Acquired Toxoplasma gondii Infection in Southern Brazil: A 28-Year Experience. Am. J. Ophthalmol., 159.","DOI":"10.1016\/j.ajo.2015.02.015"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0002-9394(02)01526-X","article-title":"An update on current practices in the management of ocular toxoplasmosis 1, 2 1InternetAdvance publication at ajo.com April 12, 2002. 2Additional information is available online at ajo.com","volume":"134","author":"Holland","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0002-9394(14)73706-7","article-title":"Current practices in the management of ocular toxoplasmosis","volume":"111","author":"Engstrom","year":"1991","journal-title":"Am. J. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00347-008-1694-2","article-title":"Diagnosis and treatment of ocular toxoplasmosis: A survey of German-speaking oph-thalmologists","volume":"105","author":"Torun","year":"2008","journal-title":"Ophthalmologe"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12639-011-0037-4","article-title":"An ophthalmologist survey-based study of the atypical presenta-tions and current treatment practices of ocular toxoplasmosis in India","volume":"35","author":"Basu","year":"2011","journal-title":"J. Parasit Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09273948.2016.1215471","article-title":"Current Practices in Ocular Toxoplasmosis: A Survey of Brazilian Uveitis Specialists","volume":"26","author":"Morais","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.actatropica.2018.04.026","article-title":"Current treatment of ocular toxoplasmosis in immunocompetent patients: A network meta-analysis","volume":"185","author":"Zhang","year":"2018","journal-title":"Acta Trop."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00436-018-6027-z","article-title":"Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review","volume":"117","author":"Montazeri","year":"2018","journal-title":"Parasitol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Dunay, I.R., Gajurel, K., Dhakal, R., Liesenfeld, O., and Montoya, J.G. (2018). Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice. Clin. Microbiol. Rev., 31.","DOI":"10.1128\/CMR.00057-17"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000449169","article-title":"Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis","volume":"57","author":"Ozgonul","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_67","first-page":"811","article-title":"Chorio-retinal toxoplasmosis: Treatment outcomes, lesion evolution and long-term follow-up in a single tertiary center","volume":"40","author":"Achiron","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/bjo.2006.100925","article-title":"Visual function in human ocular toxoplasmosis","volume":"91","author":"Scherrer","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"273506","DOI":"10.1155\/2014\/273506","article-title":"Current Treatment of Toxoplasma Retinochoroiditis: An Evidence-Based Review","volume":"2014","author":"Harrell","year":"2014","journal-title":"J. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review","volume":"17","author":"Goodwin","year":"2017","journal-title":"Drugs R&D"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","article-title":"Antibiotics for human toxoplasmosis: A systematic review of randomized trials","volume":"107","author":"Rajapakse","year":"2013","journal-title":"Pathog. Glob. Heal."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ophtha.2010.04.020","article-title":"Random-ized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis","volume":"118","author":"Soheilian","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10792-012-9634-1","article-title":"Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: A prospective randomized clinical trial","volume":"33","author":"Baharivand","year":"2013","journal-title":"Int. Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/09273948.2015.1057599","article-title":"Fulminant Ocular Toxoplasmosis: The Hazards of Corticosteroid Monotherapy","volume":"24","author":"Oray","year":"2015","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/09273948.2011.547157","article-title":"Controversies in Ocular Toxoplasmosis","volume":"19","author":"Wakefield","year":"2011","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Vedula, S.S., and Nguyen, Q.D. (2008). Corticosteroids for ocular toxoplasmosis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD007417"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archopht.1969.00990010483005","article-title":"Variations in Recurrent Active Toxoplasmic Retinochoroiditis","volume":"81","author":"Friedmann","year":"1969","journal-title":"Arch. Ophthalmol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1017\/S0950268899002800","article-title":"Incidence of symptomatic toxoplasma eye disease: Aetiology and public health implications","volume":"123","author":"Gilbert","year":"1999","journal-title":"Epidemiol. Infect."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0161-6420(02)00990-9","article-title":"Ocular toxoplasmosis: Clinical features and prognosis of 154 patients","volume":"109","author":"Berendschot","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/bjo.2007.123661","article-title":"Recurrence characteristics in European patients with ocular toxoplasmosis","volume":"92","author":"Garweg","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/infdis\/jis640","article-title":"Association of a NOD2 Gene Polymorphism and T-Helper 17 Cells with Presumed Ocular Toxoplasmosis","volume":"207","author":"Dutra","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Portillo, J.-A.C., Okenka, G., Reed, E., Subauste, A., van Grol, J., Gentil, K., Komatsu, M., Tanaka, K., Landreth, G., and Levine, B. (2010). The CD40-Autophagy Pathway Is Needed for Host Protection Despite IFN-\u0393-Dependent Immunity and CD40 Induces Autophagy via Control of P21 Levels. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014472"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1167\/iovs.10-5819","article-title":"CXCL10 Is Required to Maintain T-Cell Populations and to Control Parasite Replication during Chronic Ocular Toxoplasmosis","volume":"52","author":"Norose","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/IAE.0000000000000361","article-title":"Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosis","volume":"35","author":"Reich","year":"2015","journal-title":"Retina"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1055\/a-1141-3812","article-title":"Rezidivprophylaxe bei okul\u00e4rer Toxoplasmose","volume":"237","author":"Pleyer","year":"2020","journal-title":"Klin. Mon. Augenheilkd."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bjophthalmol-2013-304259","article-title":"Risk of reactivation of toxoplasmic retinitis following intraocular procedures without the use of prophylactic therapy","volume":"98","author":"Heringer","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/IIO.0000000000000088","article-title":"Toxoplasmic Retinitis: To Treat or Not to Treat and with What Drug?","volume":"55","author":"Barb","year":"2015","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-019-1209-8","article-title":"Morphological characteristics of ocular toxoplasmosis and its regression pattern on swept-source optical coherence tomography angiography: A case report","volume":"19","author":"Park","year":"2019","journal-title":"BMC Ophthalmol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ouyang, Y., Pleyer, U., Shao, Q., Keane, P.A., St\u00fcbiger, N., Joussen, A.M., Sadda, S.R., and Heussen, F.M. (2014). Evaluation of cystoid change phe-notypes in ocular toxoplasmosis using optical coherence tomography. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086626"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amsu.2020.04.008","article-title":"Spectral optical coherence tomography findings in patients with ocular toxoplasmosis: A case series study","volume":"54","author":"Ammar","year":"2020","journal-title":"Ann. Med. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40942-020-00231-2","article-title":"New findings useful for clinical practice using swept-source optical coherence tomography angiography in the follow-up of active ocular toxoplasmosis","volume":"6","author":"Campelo","year":"2020","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/jop.2015.0059","article-title":"Current Therapy of Acquired Ocular Toxoplasmosis: A Review","volume":"31","author":"Lima","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1055\/s-0041-111821","article-title":"Ocular Toxoplasmosis: An Update","volume":"233","author":"Garweg","year":"2016","journal-title":"Klin. Mon. Augenheilkd."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/5\/1090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:40Z","timestamp":1760160820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/5\/1090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":93,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["jcm10051090"],"URL":"https:\/\/doi.org\/10.3390\/jcm10051090","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}